Natera (NASDAQ:NTRA) Director Sells $4,132,500.00 in Stock

Natera, Inc. (NASDAQ:NTRA) Director Herm Rosenman sold 16,530 shares of the business’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $250.00, for a total value of $4,132,500.00. Following the completion of the sale, the director directly owned 4,250 shares in the company, valued at approximately $1,062,500. This represents a 79.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Natera Stock Performance

Shares of NASDAQ:NTRA opened at $261.91 on Monday. The stock has a fifty day simple moving average of $212.73 and a two-hundred day simple moving average of $215.70. Natera, Inc. has a 12-month low of $131.81 and a 12-month high of $271.47. The stock has a market capitalization of $37.51 billion, a price-to-earnings ratio of -160.68 and a beta of 1.56.

Wall Street Analyst Weigh In

NTRA has been the subject of a number of analyst reports. Royal Bank Of Canada began coverage on shares of Natera in a research note on Thursday, June 11th. They set an “outperform” rating and a $275.00 price objective for the company. Sanford C. Bernstein began coverage on shares of Natera in a research report on Friday. They set an “outperform” rating and a $310.00 price target for the company. JPMorgan Chase & Co. boosted their price objective on shares of Natera from $260.00 to $265.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Wolfe Research began coverage on Natera in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $260.00 target price on the stock. Finally, Barclays reduced their target price on Natera from $280.00 to $260.00 and set an “overweight” rating for the company in a report on Wednesday, June 24th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Natera presently has an average rating of “Moderate Buy” and a consensus target price of $259.22.

Institutional Investors Weigh In On Natera

A number of large investors have recently added to or reduced their stakes in NTRA. JPMorgan Chase & Co. boosted its stake in shares of Natera by 10.5% in the 4th quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock worth $2,944,800,000 after buying an additional 1,225,420 shares during the last quarter. Wellington Management Group LLP increased its position in Natera by 94.7% during the fourth quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock valued at $1,140,026,000 after acquiring an additional 2,420,263 shares during the last quarter. State Street Corp lifted its holdings in Natera by 2.2% in the third quarter. State Street Corp now owns 3,389,599 shares of the medical research company’s stock valued at $545,624,000 after acquiring an additional 72,087 shares during the period. Franklin Resources Inc. lifted its holdings in Natera by 37.5% in the third quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company’s stock valued at $428,987,000 after acquiring an additional 727,366 shares during the period. Finally, Coatue Management LLC boosted its position in Natera by 1,446.1% in the fourth quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock worth $603,270,000 after purchasing an additional 2,463,008 shares during the last quarter. Institutional investors own 99.90% of the company’s stock.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.